Over the last couple of years, one of the best pharma stocks to own has been Eli Lilly (NYSE: LLY). But now, an investment in ...

A once-weekly dose of tirzepatide (Mounjaro) can lead to significant, sustained weight loss for up to 3 years in adults with ...

Weight-loss drugs are being doled out within minutes in telehealth consults to patients, triggering warnings from health ...

Amy Schumer has provided fans with a comical update on her weight loss journey. The I Feel Pretty star said she tried Ozempic ...

The once-daily pill, currently under investigation, is being studied for adults with type 2 diabetes who are not on any ...

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...

We recently published a list of 10 Best Low Volatility Stocks to Buy Now. In this article, we are going to take a look at ...

Eli Lilly's new oral weight-loss pill, orforglipron, shows promise in late-stage trials across countries like India and the US. Participants experienced an average weight loss of 7.2 kg with the 36 mg ...

Westport makes the world’s entire supply of the anti-wrinkle drug — now it fears production could move to the US ...

Eli Lilly's weight-loss jab Mounjaro has been cleared for rollout by the NHS in England, with around 3.4 million people eligible, but will be made available in stages to limit the financial impact.

Long-term use of tirzepatide shows sustained and significant weight loss in adults with overweight or obesity.

In addition to lowering its price target from $105 to $64 to market perform, BMO lowered its rating on Novo Nordisk’s shares ...